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Introduction: In a phase III, randomized, double-blind study 
(PARAMOUNT), maintenance pemetrexed demonstrated significant 
benefit in advanced non–small-cell lung cancer (NSCLC). We pres-
ent safety, resource use, and quality of life (QoL) results.
Methods: After four 21-day cycles of pemetrexed-cisplatin 
(N = 939), patients with advanced nonsquamous NSCLC, whose dis-
ease had not progressed and who had a performance status of 0/1, were 
randomized 2:1 (N = 539) to maintenance pemetrexed 500 mg/m2  
plus best supportive care or placebo plus best supportive care every 
21 days until disease progression or unacceptable toxicity. QoL was 
measured using the EuroQol 5-dimensional questionnaire (EQ-5D).
Results: Frequently reported grade 3 to 4 drug-related toxicities with 
maintenance pemetrexed versus placebo were anemia (4.5% versus 
0.6%; p = 0.016), fatigue (4.2% versus 0.6%; p = 0.016), and neu-
tropenia (3.6% versus 0.0%; p < 0.006). No significant differences 
in drug-related grade 3 to 5 toxicities were observed with long-term 
pemetrexed exposure (>6 cycles), except grade 3 to 4 neutropenia, 
which did not result in increased infections. Patients on mainte-
nance pemetrexed required more transfusions (13.4% versus 5.0%; 
p = 0.003), granulocyte colony- or granulocyte-macrophage colony-
stimulating factors (5.3% versus 0.0%; p <0.001), anti-infectives 
(25.3% versus 16.7%; p = 0.028), and hospitalizations because 
of study drug (8.4% versus 3.3%, p = 0.028) than placebo-treated 
patients did. No significant treatment-by-time interactions, overall 
treatment differences, or clinically relevant changes from baseline 
were observed in EQ-5D scores during treatment.
Conclusions: Long-term use of continuation maintenance pemetrexed 
was well tolerated; resource use was low, corresponding with known 
pemetrexed toxicities. The EQ-5D results demonstrate that patients 
tolerate long-term maintenance pemetrexed without worsening QoL.
Key Words: Nonsquamous non–small-cell lung cancer, Pemetrexed, 
Maintenance, Quality of life, EuroQol 5-dimensional questionnaire.
(J Thorac Oncol. 2012;7: 1713–1721)
Until recently, the treatment paradigm for advanced non–small-cell lung cancer (NSCLC) was to wait to administer 
second-line therapy until disease progression after the induc-
tion regimen.1 However, the duration of disease control after 
response to initial chemotherapy is brief.2 With maintenance 
therapy, treatment is given to prevent progression after initial 
treatment has achieved disease control.1 In recent studies, main-
tenance therapy administered immediately after the completion 
of induction treatment and before disease progression has been 
shown to extend both progression-free survival (PFS) and overall 
survival (OS) in patients with advanced NSCLC.3,4
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Patients eligible for maintenance therapy are often 
asymptomatic and are seeking to maintain health-related 
quality of life (QoL) in addition to extending survival.5,6 Thus, 
safety and QoL are important considerations in studies of 
advanced NSCLC therapies, particularly in studies of main-
tenance therapy, which aim to improve PFS and OS without 
adversely affecting QoL. Pemetrexed has been shown to be 
efficacious and well tolerated in combination with cisplatin 
as a first-line treatment, as a single-agent after prior chemo-
therapy, and as a maintenance treatment after platinum-based 
first-line chemotherapy in patients with advanced nonsqua-
mous NSCLC.3,7,8 In both the second-line and maintenance 
studies of pemetrexed, disease-specific QoL symptoms were 
evaluated using the Lung Cancer Symptom Scale.9,10 The 
maintenance study3,10 showed statistically significant longer 
time to worsening for pain and hemoptysis in pemetrexed-
treated patients compared with placebo-treated patients.
Recently, a phase III, randomized, double-blind, 
placebo-controlled study (PARAMOUNT) was conducted 
to assess continuation maintenance treatment with peme-
trexed after a pemetrexed-containing induction regimen.11 
As previously reported, maintenance pemetrexed has dem-
onstrated significant benefit in the treatment of patients with 
advanced nonsquamous NSCLC.3,11 As a secondary objec-
tive of the PARAMOUNT study, patient-reported QoL was 
measured using the EuroQol 5-dimensional questionnaire 
(EQ-5D).12 The EQ-5D instrument has the advantage of 
being relatively easy for investigational sites to administer, 
and patients can complete the questionnaire quickly com-
pared with other QoL instruments. Here, we present the 
results of the prespecified secondary endpoints of safety, 
resource use, and QoL data from the EQ-5D questionnaire 
in the PARAMOUNT study.
PATIENTS AND METHODS
Patients
To receive induction treatment, patients were required 
to have a histologic or cytologic diagnosis of advanced (stage 
IIIB/IV) nonsquamous NSCLC based on the Lung Cancer 
Staging System version 5.13 Additional eligibility criteria 
included no prior systemic chemotherapy for lung cancer, 
including adjuvant; an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 or 114; one or more mea-
surable lesion(s) per Response Evaluation Criteria in Solid 
Tumors (1.0)15; adequate organ function; and age of 18 years 
or older. Patients receiving concurrent administration of other 
antitumor therapy were ineligible for the study.
After completing four cycles of induction treatment, 
patients were eligible to receive maintenance therapy if they 
had an ECOG performance status of 0 or 1 and documented 
radiographic evidence of complete response (CR), partial 
response (PR), or stable disease (SD). The response did not 
have to be confirmed for the patient to be randomized.
The protocol was approved by Institutional Ethics 
Review Boards. Written informed consent was obtained from 
all patients before starting induction treatment. PARAMOUNT 
was conducted in accordance with the ethical principles in the 
Declaration of Helsinki and good clinical practice.
Study Design and Treatment
This phase III, multicenter, randomized study consisted 
of two treatment periods: an induction period, in which all 
patients were treated with four cycles of pemetrexed-cisplatin, 
followed by randomization in a double-blind, placebo-
controlled continuation maintenance period. This study was 
fully powered for the primary endpoint, PFS, and for the sec-
ondary endpoint of OS. Although the sample size was deter-
mined with respect to the PFS and OS endpoints, QoL and 
resource use were prespecified secondary endpoints of the 
trial. The data reported here are from the primary endpoint 
(PFS) data cutoff.
Between November 2008 and April 2010, 939 
patients were enrolled in the induction treatment period at 
83 investigational sites in 16 countries (Australia, Belgium, 
Canada, Finland, France, Germany, Greece, India, Italy, The 
Netherlands, Poland, Portugal, Romania, Spain, Turkey, and 
the United Kingdom).11 The induction treatment consisted of 
pemetrexed 500 mg/m2 (ALIMTA, Eli Lilly and Company, 
Indianapolis, IN) and cisplatin 75 mg/m2 on day 1 of each 
21-day cycle.
After completion of cycle 4 of the induction period, 539 
qualified patients were randomly assigned11 in a 2:1 ratio to 
maintenance treatment with pemetrexed 500 mg/m2 plus best 
supportive care (BSC) (pemetrexed arm) or to placebo plus 
BSC (placebo arm) on day 1 of each 21-day cycle until dis-
ease progression or unacceptable toxicity. Randomization was 
stratified for the following three prognostic factors: ECOG 
performance status just before randomization (0 versus 1), 
tumor response to induction chemotherapy (CR/PR versus 
SD), and disease stage before administration of induction 
therapy (IIIB versus IV). A maximum of 7 days was allowed 
from the time of randomization to the start of maintenance 
therapy. Maintenance therapy was required to begin within 
21 to 42 days from day 1 of the fourth cycle of induction 
therapy. Maintenance therapy was discontinued because of 
disease progression, unacceptable toxicity, or patient or phy-
sician decision. All patients were to be followed until death 
or study closure.
BSC was defined as treatment without a specific 
antineoplastic regimen, given with the intent to maximize 
QoL, as determined by the treating physician. BSC specifically 
excluded anticancer surgery, immunotherapy, radiation to 
intrathoracic structures, anticancer hormonal therapy, and 
systemic chemotherapy in which the goal was to either 
eradicate or slow disease progression. During both periods of 
the study, treatment (both pemetrexed and placebo) was fully 
supplemented with folic acid, vitamin B
12
, and prophylactic 
dexamethasone as per the pemetrexed label.
Safety, Resource Use, and QoL Assessments
Safety was evaluated by routine assessments of adverse 
events (AEs), standard laboratory tests, and physical examina-
tion (weight, blood pressure, and pulse). Safety evaluations 
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were based on the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 
3.0.16 Resource use included the use of concomitant medi-
cations, transfusions, treatment-related hospitalizations, and 
BSC measures and was evaluated separately for the induc-
tion and maintenance periods. Assessment of resource use 
did not include folic acid, vitamin B
12
, or dexamethasone as 
these were mandatory for all patients to receive throughout 
the study. Investigators followed current American Society 
of Clinical Oncology and European Society for Medical 
Oncology guidelines for the use of colony-stimulating factors 
and erythropoiesis-stimulating agents.
The EQ-5D is a self-administered health-status ques-
tionnaire consisting of two parts.12 The first part includes 
five descriptive questions with which the patient rates his/
her health regarding mobility, self care, usual activities, 
pain/discomfort, and anxiety/depression. Each of the five 
attributes has three levels: no problem, some problems, and 
major problems, thus defining 243 possible health states, to 
which the EuroQol committee added unconscious and dead 
for a total of 245. The possible values for health utility ranges 
from −0.59 (severe problems in all 5 dimensions) to 1.0 (no 
problem in any dimension) on a scale in which 0 represents 
death and 1 represents the best possible health state.17 The 
second part of the EQ-5D is a visual analog scale (VAS) that 
allows patients to rate their present health status. Possible 
scores range from 0 (worst imaginable health state) to 100 
(best imaginable health state).18
The 245 health states defined by the five-dimensional 
descriptive system were converted into a weighted health-state 
index by applying a method described in detail by Dolan.19 This 
method permits the measurement of preferences. Population-
based index scores have been established for both the United 
States and the United Kingdom. The U.K. population-based 
weights were used in this study, as the majority of the patients 
were at sites in Europe (90.2%) and there were no sites in the 
United States.
The EQ-5D was completed by only those patients 
for whom a translation was available in his/her native lan-
guage. Patients completed the EQ-5D questionnaire once 
at baseline (after consent but before the start of induction 
treatment, within 2 weeks of cycle 1), at each visit (once 
per cycle) before treatment administration, and once during 
the 30-day postdiscontinuation follow-up visit. The day-1, 
cycle-1 assessment was not required to be completed if the 
baseline assessment was completed within 7 days before day 
1 of cycle 1.
Statistical Considerations
Patients were included in the evaluation of safety and 
resource use if they were treated with at least one dose of 
pemetrexed or cisplatin during the induction period or if they 
were randomized and treated with at least one dose of peme-
trexed or placebo during the maintenance period. Safety and 
resource use were summarized for all patients enrolled in the 
induction period and for all randomized patients in the main-
tenance period by treatment arm. In addition, Fisher’s exact 
test was used to compare safety and resource use by treatment 
arms in the maintenance period.
All patients who provided a baseline assessment and at 
least one subsequent assessment were included in the EQ-5D 
analysis. Compliance was defined as the number of com-
pleted EQ-5D assessments divided by the number of expected 
EQ-5D assessments (i.e., patients still on study at that time). 
The U.K. population-based index scores and VAS ratings were 
summarized for all enrolled patients at baseline, at each cycle 
of treatment during the induction period, at each cycle of treat-
ment during the maintenance period by randomized treatment 
arms, and at the 30-day postdiscontinuation visit. Frequency 
distributions, including measures of central tendency and vari-
ability (e.g., means, medians, and standard deviations), were 
calculated for individual items and for the total scale. Index 
and VAS scores during the induction period were analyzed 
using a paired t test, comparing patients’ induction baseline 
values with postbaseline values at each cycle. Mean changes 
from baseline by treatment arm were compared at each main-
tenance cycle using a paired t test. In addition, the index and 
VAS scores were analyzed using a mixed-effects analysis of 
variance model to determine whether the maintenance peme-
trexed and placebo profiles differed over time (from random-
ization through the last assessment after discontinuation).
Changes in ECOG performance status from baseline 
to the last maintenance treatment value were summarized by 
treatment arm and compared using a Student’s t test.
RESULTS
Patient Characteristics
Of the 939 patients who received induction therapy, 
539 were randomized to maintenance treatment: 359 to 
pemetrexed and 180 to placebo. The majority of randomized 
patients were men (58.1%) and white (94.6%), with a median 
age of 61.4 years. In total, 90.7% of the patients had stage 
IV disease, 31.5% of the patients had an ECOG performance 
status of 0, and 67.9% had an ECOG performance status of 1. 
Of the randomized patients, 44.9% had a best tumor response 
during induction therapy of CR or PR, and 51.9% had SD. 
The two treatment arms were well balanced with respect to 
key baseline characteristics and prognostic factors (Table 1).
Safety
During the induction period, 67.8% of the patients 
completed four cycles of pemetrexed-cisplatin. Discontinuations 
because of AEs (regardless of causality) occurred in 9.4% of 
the patients during the induction period. The most commonly 
reported (in ≥ 5% of patients) possibly drug-related grade 
3 to 4 AE in the induction period was neutropenia (8.4%). 
Commonly reported (in ≥ 5% of patients) possibly drug-
related grade 1 to 2 AEs in the induction period were nausea 
(33.3%), fatigue (24.7%), vomiting (18.1%), anemia (13.6%), 
neutropenia (8.8%), anorexia (8.7%), constipation (7.9%), and 
diarrhea (7.5%).
The median number of maintenance cycles administered 
was four for both the pemetrexed arm (mean = 4.9) and placebo 
arm (mean = 4.2). Discontinuations because of AEs (regardless 
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of causality) occurred in 9.2% of patients on the maintenance 
pemetrexed arm compared with 3.9% of patients on the pla-
cebo arm. Table 2 shows the rate of AEs possibly related to 
the study drug as determined by the investigator. The grade 
3 to 4 AEs with a statistically significant higher frequency 
on the pemetrexed arm compared with placebo were anemia 
(4.5% versus 0.6%; p = 0.016), fatigue (4.2% versus 0.6%; p 
= 0.016), and neutropenia (3.6% versus 0.0%; p <0.006). The 
following possibly drug-related grade 1 to 2 AEs had a statisti-
cally significant higher frequency on the pemetrexed arm com-
pared with placebo: nausea (10.6% versus 2.2%; p <0.001), 
anemia (9.5% versus 3.9%; p = 0.024), vomiting (5.8% ver-
sus 1.7%; p = 0.027), and neutropenia (4.7% versus 0.6%; p 
= 0.009). Other possibly drug-related AEs on the maintenance 
pemetrexed arm (compared with the placebo arm) included 
dermatologic/skin toxicities (rash/desquamation, alopecia, 
pruritis/itching) in 3.3% versus 6.1% of patients and renal tox-
icities as follows: decreased glomerular filtration rate (1.7% 
per arm), increased creatinine clearance (1.4% versus 1.1%), 
decreased creatinine clearance (0.3% versus 0.6%), and renal 
failure (0.6% versus 0.0%). With the exception of renal failure 
(grade 3 event in 2 patients on maintenance pemetrexed), all of 
these skin and renal toxicities were grade 1 or 2. None of the 
treatment differences were statistically significant.
During the maintenance period, 23.4% of pemetrexed-
treated patients completed more than six cycles, for a total 
of 11+ cycles of pemetrexed (4 induction cycles plus > 6 
maintenance cycles), compared with 13.9% of placebo-
treated patients completing more than six maintenance cycles 
(p = 0.009). No significant differences in drug-related grade 
3 to 5 toxicities were observed with long-term pemetrexed 
exposure, except grade 3 to 4 neutropenia, which was observed 
in 8.3% of the patients receiving more than six maintenance 
pemetrexed cycles versus 2.2% of patients receiving six or 
fewer maintenance pemetrexed cycles (p = 0.015). The greater 
incidence of neutropenia with long-term pemetrexed exposure, 
however, did not result in increased grade 3 to 5 infections 
(1.2% of patients receiving > 6 maintenance cycles versus 
2.9% of patients receiving ≤ 6 maintenance cycles; p = 0.691). 
Regarding possibly drug-related grade 1 to 2 AEs, statistically 
significant differences were observed between patients who 
received more than six pemetrexed cycles versus six or fewer 
cycles for nausea (16.7% versus 8.7%; p = 0.044), neutropenia 
(11.9% versus 2.5%; p = 0.001), sensory neuropathy (6.0% 
TABLE 1.  Baseline Patient and Disease Characteristics by 
PARAMOUNT Treatment Period
Characteristic
Induction Maintenance
Pemetrexed + 
Cisplatin (N = 939)
Pemetrexed  
(N = 359)
Placebo  
(N = 180)
Sex, n (%)
 Male 577 (61) 201 (56) 112 (62)
 Female 362 (39) 158 (44) 68 (38)
Age
 Median (range), yrs 61 (24–83) 61 (32–79) 62 (35–83)
 <65 yrs, n (%) 619 (66) 238 (66) 112 (62)
 ≥65 yrs, n (%) 320 (34) 121 (34) 68 (38)
Origin, n (%)
 Asian 59 (6) 16 (4) 8 (4)
 African 7 (0.7) 4 (1) 1 (0.6)
 White 871 (93) 339 (94) 171 (95)
 Multiple 2 (0.2) 0 (0) 0 (0)
Smoking status, n (%)
 Ever smoker 757 (81) 275 (77) 144 (80)
 Never smoker 175 (19) 82 (23) 34 (19)
 Unknown 7 (0.7) 2 (0.6) 2 (1)
ECOG PS, n (%)
 0 300 (32) 115 (32) 55 (31)
 1 639 (68) 243 (68) 123 (68)
 2-3a 0 (0) 1 (0.3) 2 (1)
Disease stage, n (%)b
 IIIB 99 (11) 31 (9) 19 (11)
 IV 840 (89) 328 (91) 161 (89)
Best tumor response to  
induction therapy, n (%)
 Complete/partial response NA 166 (46) 76 (42)
 Stable disease NA 186 (52) 94 (52)
 Progressive diseasea NA 1 (0.3) 3 (2)
 Unknowna NA 6 (2) 7 (4)
Percentages for some characteristics may not add to 100% due to rounding.
aRandomized patients with an ECOG PS of 2 or 3, or a best response to induction 
therapy of progressive disease or unknown were considered protocol violations.
bLung Cancer Staging System, version 5.13
ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not applicable.
TABLE 2.  CTCAEs Possibly Related to Study Drug Occurring 
During Maintenance Treatment in PARAMOUNT
Toxicitya
Grade 1–2, n (%) Grade 3–4,b n (%)
Pemetrexed  
(N = 359)
Placebo  
(N = 180)
Pemetrexed  
(N = 359)
Placebo  
(N = 180)
Laboratory
 Anemia 34 (10)c 7 (4)c 16 (4)c  1 (0.6)c
 Neutropenia 17 (5)c  1 (0.6)c 13 (4)c 0 (0)c
Nonlaboratory
 Fatigue (asthenia, 
 lethargy, malaise)
44 (12) 18 (10) 15 (4)c  1 (0.6)c
 Anorexia 13 (4) 2 (1) 1 (0.3) 0 (0)
 Constipation 8 (2) 5 (3) 0 (0) 0 (0)
 Diarrhea 10 (3) 3 (2) 0 (0) 0 (0)
 Mucositis/stomatitis 17 (5) 4 (2) 1 (0.3) 0 (0)
 Nausea  38 (11)c  4 (2)c 1 (0.3) 0 (0)
 Vomiting  21 (6)c  3 (2)c 0 (0) 0 (0)
 Edema 17 (5) 6 (3) 0 (0) 0 (0)
 Neuropathy: sensory 9 (3) 9 (5) 1 (0.3) 1 (0.6)
 Watery eye (epiphora, 
 tearing)
9 (3) 1 (0.6) 0 (0) 0 (0)
 Pain 11 (3) 3 (2) 3 (0.8) 0 (0)
aToxicities were reported using CTCAE version 3.0 (National Cancer Institute 
2006). Toxicities occurring in ≥ 3% of patients on either or both arms are listed.
bTwo grade 5 events (deaths) considered possibly related to study drug occurred 
during the maintenance period: pemetrexed- pneumonia; placebo-sudden death.
cDifference between treatment arms is statistically significant (Fisher’s exact test p ≤ 0.05).
CTCAE, Common Terminology Criteria for Adverse Events.
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versus 1.5%; p = 0.036), ocular/visual events (13.1% versus 
2.5%; p < 0.001), and headache (3.6% versus 0.4%; p = 0.041).
Resource Use
Resource use was higher with pemetrexed-cisplatin dur-
ing the induction period than with single-agent pemetrexed dur-
ing the maintenance period, including antiemetic use (66.7% 
compared with 34.0%; Table 3) and hospitalizations because of 
drug-related AEs (13.4% compared with 8.4%; Table 4).
During the maintenance period, a higher percentage of 
patients on the pemetrexed arm required the following con-
comitant medications compared with patients on the placebo 
arm: transfusions (13.4% versus 5.0%, p = 0.003), granulo-
cyte colony- or granulocyte-macrophage colony-stimulating 
factors (5.3% versus 0.0%, p < 0.001), and anti-infectives 
(25.3% versus 16.7%, p = 0.028; Table 3). The overall rate 
of hospitalizations because of AEs was similar between treat-
ment arms (pemetrexed = 19.2% and placebo = 17.8%; p = 
0.727; Table 4). The maintenance pemetrexed arm had a higher 
rate of hospitalizations because of drug-related AEs compared 
with the placebo arm (8.4% versus 3.3%, p = 0.028; Table 4).
Quality of Life
Overall EQ-5D compliance during the induction period 
was 79.4% (3206 assessments completed of 4039 visits). The 
most common reasons for missing assessments were inabil-
ity to contact the patient (51% of missing questionnaires) and 
failure by study sites to administer the questionnaire (27% of 
missing questionnaires). A translation of the EQ-5D was not 
available for 19 patients (3 patients in Belgium, 3 patients in 
France, and 13 patients in India).
During the induction period, statistically significant 
improvements from baseline were observed in EQ-5D 
index scores at cycle 3 (mean change from baseline 0.03, 
p = 0.003) and cycle 4 (mean change from baseline 0.03, 
TABLE 3.  Concomitant Medications, Nutritional Support, 
and Supportive Care Procedures in PARAMOUNT
Induction Maintenance
Pemetrexed  
+ Cisplatin  
(N = 939) %
Pemetrexed 
(N = 359)  
%
Placebo  
(N = 180) 
%
pa
Concomitant medications
 Analgesics 56.7 48.7 51.7 0.524
 Antiemetics 66.7 34.0 36.1 0.633
 Anti-infectives 26.9 25.3 16.7 0.028
 ESAs 6.5 10.9 6.1 0.084
 Transfusions 10.3 13.4 5.0 0.003
 G-CSF or GM-CSF 6.5 5.3 0.0 <0.001
Nutritional supportb
 Oral 3.2 1.4 0.0 0.175
Procedures: supportive careb
 C omputed tomography, 
spiral
2.9 0.0 0.0 —
 Electrocardiogram 3.0 0.8 0.0 0.554
 Examination, laboratory 2.7 0.0 0.0 —
 Examination, physical 2.6 0.0 0.0 —
 Examination, vital sign 2.6 0.0 0.0 —
 Ex trathoracic palliative  
radiotherapy
4.6 0.6 3.3 0.019
 Injection 2.6 0.8 0.0 0.554
 Insertion, portacath 2.3 0.0 0.0 —
 In travenous fluid  
administration
2.9 0.8 0.0 0.554
 Thoracentesis 2.3 1.1 0.6 0.669
 Radiograph, chest 2.0 0.0 0.0 —
aFisher’s exact test p value comparing maintenance treatments. Significant if p ≤ 
0.05.
bReported for ≥ 2% of patients in either treatment period or maintenance arm.
ESA, erythropoietic-stimulating agents; G-CSF, granulocyte colony-stimulating 
factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
TABLE 4.  Summary of All Hospitalizations Because of AEs in PARAMOUNT
Induction Maintenance
Pemetrexed + Cisplatin (N = 939) Pemetrexed (N = 359) Placebo (N = 180) pa
Patients with at least 1 hospitalization, n (%) 229 (24.4) 69 (19.2) 32 (17.8) 0.727
 All hospitalizations 295 91 37
 Mean (SD) length of stay, nights 7.87 (7.18) 8.57 (7.01) 8.95 (9.66) 0.807
 Median (range) length of stay, nights 5.00 (0.00, 45.00) 6.00 (1.00, 34.00) 6.00 (1.00, 53.00)
Patients hospitalized because of drug-related AEs, n (%) 126 (13.4) 30 (8.4) 6 (3.3) 0.028
 Hospitalizations involving drug-related AEs 148 35 7
 Mean (SD) length of stay, nights 8.08 (7.06) 8.14 (7.00) 10.57 (8.26) 0.421
 Median (range) length of stay, nights 6.00 (0.00, 45.00) 6.00 (1.00, 31.00) 9.00 (2.00, 27.00)
Patients hospitalized because of nondrug-related AEs, n (%) 139 (14.8) 48 (13.4) 26 (14.4) 0.791
 Hospitalizations not involving drug-related events 167 63 30
 Mean (SD) length of stay, nights 8.13 (7.34) 9.17 (7.03) 9.77 (10.40) 0.747
 Median (range) length of stay, nights 5.00 (0.00, 37.00) 8.00 (1.00, 34.00) 6.00 (1.00, 53.00)
aFisher’s exact test p value comparing maintenance treatments. Significant if p ≤ 0.05.
SD, standard deviation; AEs, adverse events.
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p = 0.001) (Fig. 1A). No significant VAS changes were 
observed during the induction period, although numerical 
improvement on the VAS was observed at cycle 3 (mean 
change from baseline 0.60) and cycle 4 (mean change from 
baseline 1.13) (Fig. 1B).
Overall EQ-5D compliance for randomized patients 
during the maintenance period was 84.3% for the peme-
trexed arm (1834 assessments completed of 2176 visits) and 
80.9% for the placebo arm (807 assessments completed of 
998 visits). At the postdiscontinuation visit, at which the most 
worsening could be anticipated, 43.9% of pemetrexed-treated 
patients and 44.3% of placebo-treated patients completed the 
EQ-5D. The most common reason for missing assessments 
during the maintenance period was failure by study sites to 
administer the questionnaire (32% of missing questionnaires 
on the pemetrexed arm and 26% of missing questionnaires on 
the placebo arm).
During the maintenance period, neither significant 
treatment-by-time interactions nor overall treatment differences 
were observed in the mixed-effects model repeated measures 
FIGURE 1. A, EQ-5D U.K. population-based 
index score during induction: all enrolled 
patients. B, EQ-5D VAS rating during  
induction: all enrolled patients. EQ-5D, 
EuroQol 5-dimensional questionnaire; VAS, 
visual analog scale.
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analyses of the EQ-5D index score and VAS rating (data not 
shown). In the comparison of treatment differences using a 
paired t test, statistically significant differences were observed 
between the pemetrexed and placebo arms in mean changes 
from baseline on the index score at cycle 6 (pemetrexed −0.02, 
placebo 0.04, p = 0.050; Fig. 2A) and the VAS rating at cycle 
4 (pemetrexed 0.69, placebo 6.15, p = 0.010) and cycle 5 
(pemetrexed 1.55, placebo 5.99, p = 0.044; Fig. 2B). However, 
the changes from baseline were not clinically relevant according 
to the minimally important differences (MIDs) for lung cancer 
(0.08 for the U.K. population-based index score and 7 for the 
VAS score) determined by Pickard and colleagues.20 The MID 
is defined as the smallest change in a patient-reported outcome 
measure that is perceived by patients as beneficial or that would 
result in a change in treatment.20 No statistically significant 
differences were observed between treatment arms after cycle 
6 (data not shown).
The majority of worsening in QoL as captured by the 
EQ-5D instrument was observed at postdiscontinuation visits. 
At the postdiscontinuation visit, the change from baseline in 
the index score was −0.13 on the pemetrexed arm and −0.09 
on the placebo arm. Although this treatment difference for the 
index score was not statistically significant, the magnitude of 
the changes on both treatment arms was considered clinically 
relevant worsening according to the lung cancer MID.20 For 
the VAS rating at the postdiscontinuation visit, the change 
from baseline was −4.77 on the pemetrexed arm and −3.92 on 
the placebo arm; this treatment difference was not statistically 
significant, nor was it considered clinically relevant.
In addition, the analysis of performance status changes 
from baseline showed no differences between the maintenance 
pemetrexed and placebo arms (p = 0.3673). The majority of 
the patients were able to maintain performance status (77.8% 
on pemetrexed, 77.3% on placebo), and a similar number of 
patients between treatment arms showed an improvement 
(7.5% on pemetrexed, 10.2% on placebo) or a worsening in 
performance status (14.7% on pemetrexed, 12.6% on pla-
cebo). At baseline, 31.5% of the patients had a performance 
status of 0 and 67.9% of the patients had a performance status 
of 1 (Table 1). Of patients with a baseline performance status 
of 1, 42 improved (25 on pemetrexed and 17 on placebo). The 
low percentage of patients with improvement from perfor-
mance status 1 to performance status 0 was expected, as per-
formance status improvement from 1 to 0 is clinically difficult 
(i.e., from symptomatic to asymptomatic).
DISCUSSION
PARAMOUNT demonstrated a statistically significant 
improvement in PFS for patients treated with continuation 
maintenance pemetrexed compared with those treated with 
placebo after pemetrexed-cisplatin induction treatment.11
The safety profile of the pemetrexed-cisplatin induc-
tion treatment in PARAMOUNT was generally similar to the 
previous study of pemetrexed-cisplatin as a first-line treat-
ment.8 With the exception of neutropenia (8.4%), grade 3 to 
4 toxicities were uncommon (<5%) during induction. Several 
toxicities traditionally associated with cisplatin were observed 
during induction; specifically, nausea, fatigue, vomiting, and 
anemia were the most common grade 1 to 2 toxicities during 
induction. Resource use for management of toxicities dur-
ing the induction period was also common for antiemetics 
(66.7%) and hospitalizations for drug-related AEs (13.4%), 
likely because of the inclusion of cisplatin.
The toxicities observed with single-agent maintenance 
pemetrexed in PARAMOUNT were consistent with those in 
the previous study of maintenance pemetrexed,3 including the 
low incidence (< 5%) of grade 3 to 4 anemia, fatigue, and 
neutropenia and grade 1 to 2 (approximately ≤ 10%) nausea, 
anemia, vomiting, and neutropenia. Clinically relevant skin 
and renal toxicities (traditionally associated with pemetrexed, 
which have been recently described in the literature)21,22 were 
rare, primarily grade 1 to 2 events, with a similar incidence 
between continuation maintenance pemetrexed and placebo 
treatment arms. The increase in grade 3 to 4 neutropenia for 
more than six maintenance cycles of pemetrexed compared 
with six or fewer maintenance cycles (8.3% versus 2.2%; p = 
0.015) did not result in an increased incidence of infections 
(1.2% and 2.9%, respectively; p = 0.691). The rate of 
discontinuations because of AEs, an important indicator 
of treatment intolerance, was low (9% on maintenance 
pemetrexed versus 4% on placebo). The higher percentage of 
patients who received more than six cycles of maintenance 
on the pemetrexed arm versus placebo (23.4% versus 13.9%, 
p = 0.009) demonstrated that pemetrexed maintenance therapy 
was well tolerated for extended durations of treatment.
Resource use during the maintenance period was low 
and comparable to studies of single-agent pemetrexed in 
advanced NSCLC.3,7,10 Use of transfusions, colony-stimulating 
factors, anti-infectives, and hospitalizations because of study 
drug were significantly higher with maintenance pemetrexed, 
but the differences were small (5%–8%) when compared with 
placebo. Use of these resources during maintenance treat-
ment with single-agent pemetrexed corresponded with small 
increases of approximately 4% in grade 3 to 4 anemia, fatigue, 
and neutropenia and small increases of approximately 4% to 
8% in grade 1 to 2 nausea, anemia, vomiting, and neutropenia 
compared with placebo.
On the basis of the EQ-5D results, no overall treatment 
differences in QoL were observed, demonstrating that main-
tenance pemetrexed did not have a detrimental effect on QoL. 
In addition, no clinically relevant differences were observed at 
any visit during the treatment period based on MIDs for lung 
cancer (0.08 for the U.K. population-based index score and 7 
for the VAS) determined by Pickard and colleagues,20 dem-
onstrating that patients on both arms maintained their QoL 
during treatment. As expected, the majority of worsening was 
observed at the postdiscontinuation visit (i.e., at the time of 
disease progression or toxicity leading to discontinuation from 
study treatment). Compliance on the questionnaire was lowest 
at the postdiscontinuation visit, and the mean changes in the 
EQ-5D index scores for both pemetrexed and placebo (−0.13 
and −0.09, respectively) were clinically relevant according to 
the MID of 0.08, although the difference between the treat-
ment arms was not statistically significant.
The lack of significant treatment differences in QoL 
based on the EQ-5D instrument is further supported by the 
similarity between treatment arms in the change from baseline 
performance status. The relatively good overall QoL of these 
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patients (based on the EQ-5D results) was further supported 
by their performance status (0 or 1). The well-tolerated safety 
profile, EQ-5D results, and the performance-status changes 
demonstrate that the majority of the patients were able to 
maintain their overall good QoL.
There are known limitations of the EQ-5D instrument 
in the cancer population, including the limited ability of the 
three-level response version used to capture small changes 
(ceiling effects) in health status.23 Another limitation of the 
EQ-5D instrument in the cancer population is its lack of a 
vitality dimension.24 The EQ-5D captures a dimension for 
usual activities, but by itself, this dimension may not ade-
quately account for vitality in cancer, in particular cancer-
related fatigue.24,25 However, previous studies of single-agent 
pemetrexed did include a cancer-specific QoL instrument with 
a fatigue dimension, the Lung Cancer Symptom Scale.7,9,10 
The previous maintenance study of pemetrexed10 found no 
significant differences between maintenance pemetrexed and 
placebo treatment arms in the assessment of fatigue responses, 
including time to worsening of fatigue, although conclusions 
were limited by the high rate of censoring (> 50%). In both 
the previous single-agent pemetrexed studies,7,10 the incidence 
FIGURE 2. A, EQ-5D U.K. population-
based index score during maintenance: 
all randomized patients. B, EQ-5D VAS 
rating during maintenance: all randomized 
patients. EQ-5D, EuroQol 5-dimensional 
questionnaire; VAS, visual analog scale.
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of grade 3 to 4 fatigue with pemetrexed was similar to that 
observed in PARAMOUNT.
In conclusion, the safety profile of single-agent con-
tinuation maintenance pemetrexed in PARAMOUNT was 
similar to that observed in the previous single-agent main-
tenance study of pemetrexed.3 Resource use during mainte-
nance treatment was generally low and as expected, given 
the toxicities observed in PARAMOUNT and other stud-
ies of single-agent pemetrexed therapy.3,7,10 No overall sta-
tistical or clinically relevant differences in health status 
were observed on the EQ-5D between patients treated with 
maintenance pemetrexed and patients treated with placebo 
in PARAMOUNT. Thus, in addition to the PFS benefit and 
well-tolerated safety profile,11 patients were able to maintain 
their good QoL over the course of continuation maintenance 
pemetrexed therapy without requiring extensive resource use 
to manage adverse effects.
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